A benefit-risk assessment of agomelatine in the treatment of major depression

Drug Safety

Volumn 34, Issue 9, 2011, Pages 709-731

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Agomelatine; Benefit risk assessment; Depression; Major depressive disorder

Indexed keywords

AGOMELATINE; ALCOHOL; ANTIDEPRESSANT AGENT; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; DOPAMINE; FLUOXETINE; FLUVOXAMINE; LITHIUM; LORAZEPAM; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MOOD STABILIZER; NORADRENALIN; PAROXETINE; PLACEBO; RAMELTEON; SEROTONIN; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SERTRALINE; VALPROIC ACID; VALPROMIDE; VENLAFAXINE;

ABNORMAL DREAMING; AGITATION; ANTIANXIETY ACTIVITY; ANTIDEPRESSANT ACTIVITY; ANXIETY; BIPOLAR DISORDER; BODY WEIGHT; CARDIOVASCULAR DISEASE; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ACTIVITY; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; HUMAN; HYPOMANIA; INSOMNIA; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FUNCTION; LIVER METABOLISM; LONG TERM CARE; MAJOR DEPRESSION; MANIA; MEDLINE; MENTAL DISEASE; META ANALYSIS (TOPIC); METABOLIC DISORDER; NAUSEA; NONHUMAN; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; PSYCINFO; RECEPTOR BLOCKING; RELAPSE; REVIEW; RHINITIS; RISK BENEFIT ANALYSIS; SEASONAL AFFECTIVE DISORDER; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP PARAMETERS; SLEEP QUALITY; SLEEP WAKING CYCLE; SLOW WAVE SLEEP; SOMNOLENCE; SWEATING; UPPER ABDOMINAL PAIN; URINARY EXCRETION; VOMITING; WEIGHT CHANGE; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

ACETAMIDES; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, MELATONIN; RISK ASSESSMENT; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 80051617616     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11593960-000000000-00000     Document Type: Review

References (68)

1. Hirschfeld RMA, Weissman MM. Risk factors for major depression and bipolar disorder. In: Davis KL, Charney D, Coyle JT, et al., editors. Neuropsychopharmacology: the fifth generation of progress. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 1017-25
2. Browne G, Steiner M, Roberts J, et al. Prevalence of dysthymic disorder in primary care. J Affect Disord 1999; 54: 303-8 (Pubitemid 29329440)
3. Kessler RC, Zhao S, Blazer DG, et al. Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey. JAffect Disord 1997; 45: 19-30 (Pubitemid 27357460)
4. Howland RH. Health status, health care utilization, and medical comorbidity in dysthymia. Int J Psychiatry Med 1993; 23 (3): 211-38 (Pubitemid 23310295)
5. Howland RH, Schettler PJ, Rapaport MH, et al. Clinical features and functioning of patients with minor depression. Psychother Psychosom 2008; 77: 384-9
6. Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP task force on response and remission in major depression. Neuropsychopharmacol 2006; 31: 1841-53
7. Koplan C, Charuvastra A, Compton MT, et al. Prevention psychiatry. Psychiatr Ann 2007; 37: 319-28
8. Baune BT, Adrian I, Jacobi F. Medical disorders affect health outcome and general functioning depending on comorbid major depression in the general population. J Psychosomatic Res 2007; 62: 109-18 (Pubitemid 46161593)
9. Howland RH. Therapeutic armamentarium for treating depression. Postgrad Med 2010; 122 (4): 66-93
10. de Bodinat C, Guardiola-Lemaitre B, Mocaer E, et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization, and development. Nat Rev Drug Discov 2010; 9 (8): 628-42
11. European Medicines Agency. CMHP assessment report for valdoxan. 20 November 2008 [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Public-assessment-report/human/000915/WC500046226.pdf [Accessed 2011 Jul 13]
12. European Medicines Agency, Committee for Medicinal Products for Human Use. Summary of positive opinion for valdoxan. 20 November 2008. Doc. Ref. EMEA/CHMP/575411/2008 [online]. Available from URL: http://www.emea.europa.eu/ pdfs/human/opinion/Valdoxan-5754 1108en.pdf [Accessed 2011 Jul 13]
13. European Medicines Agency. Valdoxan product information: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product-Information/human/000915/WC500046227. pdf [Accessed 2011 Jul 13]
14. United States Food andDrugAdministration [online]. Available from URL: http://www.fda.gov/[Accessed 2011 Jul 13]
15. ClinicalTrials.gov, a service of the US National Institutes of Health [online]. Available from URL: http://www.clini caltrials.gov [Accessed 2011 Jul 13]
16. Zlotos DP. Recent advances in melatonin receptor ligands. Arch Pharm Chem Life Sci 2005; 338: 229-47 (Pubitemid 40957262)
17. Rajaratnam SMW, Cohen DA, Rogers NL. Melatonin and melatonin analogues. Sleep Med Clin 2009; 4: 179-93
18. Landolt HP, Wehrle R. Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition, and mood? Eur J Neurosci 2009; 29: 1795-809
19. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine is an antagonist at 5-hydoxytryptamine-2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306 (3): 954-64 (Pubitemid 37025301)
20. Quera-Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol 2007; 10: 691-6 (Pubitemid 47517524)
21. Kupfer DJ. Depression and associated sleep disturbances: patient benefits with agomelatine. Eur Neuropsychopharmacol 2006; 16 Suppl. 5: S639-43 (Pubitemid 44528983)
22. Leproult R, Van Onderbergen A, L'Hermite-Baleriaux M, et al. Phase-shifts of 24-h rhythms of hormonal release and body termperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol 2005; 63: 298-304 (Pubitemid 41233447)
23. Descamps A, Rousset C, Millan M, et al. Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture. Psychopharmaology 2009; 2005: 93-106
24. Racagni G, Riva MA, Popoli M. The interaction between the internal clock and antidepressant efficacy. Int Clin Psychopharmacol 2007; 22 Suppl. 2: S9-14 (Pubitemid 47530848)
25. Sharpley AL, Rawlings NB, Brain S, et al. Does agomelatine block 5-HT2c receptors in humans? Psychopharmacology 2011; 213 (2-3): 653-5
26. Hale A, Corral RM, Mencacci C, et al. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized double-blind study. Int Clin Psychopharmacol 2010; 25: 305-14
27. Loo H, Hale A, D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17 (5): 239-47
28. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16 (2): 93-100 (Pubitemid 43145814)
29. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10: 661-73 (Pubitemid 47517525)
30. Zajecka J, Schatzberg A, Stahl S, et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder. J Clin Psychopharmacol 2010; 30: 135-44
31. Stahl SM, Fava M, Trivedi MH, et al. Agomelatine in the treatment of major depressive disorder: an 8-week multicenter randomized placebo-controlled trial. J Clin Psychiatry 2010; 71 (5): 616-26
32. Novartis. Clinical trial results database [online]. Available from URL: http://www.novctrd.com/ctrdWebApp/clin icaltrialrepository/public/login.jsp [Accessed 2011 Jul 13]
33. Goodwin GM, Emsley R, Rembry S, et al. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized double-blind placebo-controlled trial. J Clin Psychiatry 2009; 70 (8): 1128-37
34. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
35. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9 (Pubitemid 9136500)
36. Novartis. A placebo-and paroxetine-controlled study of the efficacy, safety and tolerability of agomelatine (25 or 50 mg) in the treatment of major depressive disorder (MDD) [ClinicalTrials.gov identifier NCT00463242]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jul 13]
37. Novartis. Efficacy, safety and tolerability of agomelatine in the treatment of major depressive disorder [ClinicalTrials. gov identifier NCT00411242].US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jul 13]
38. Novartis. Efficacy, safety and tolerability of agomelatine in the treatment of major depressive disorder [ClinicalTrials. gov identifier NCT00411099].US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jul 13]
39. Novartis. Efficacy, safety and tolerability of agomelatine in the prevention of relapse of major depressive disorder [ClinicalTrials.gov identifier NCT00467402]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jul 13]
40. Novartis. Efficacy, safety and tolerability of agomelatine sublingual tablets in the treatment of major depressive disorder [ClinicalTrials.gov identifier NCT01110889]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jul 13]
41. Novartis. Efficacy, safety and tolerability of agomelatine sublingual tablets in the treatment of major depressive disorder (MDD) [ClinicalTrials.gov identifier NCT01110902]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jul 13]
42. Novartis. Open-label long term (52 weeks) safety and tolerability of agomelatine sublingual tablets inmajor depressive disorder (MDD) [ClinicalTrials.gov identifier NCT01156415]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jul 13]
43. Guy W. Clinical Global Impression (CGI) ECDEU Assessment Manual for Psychopharmacology. US Department of Health Education and Welfare publication (ADM); 1976: 76-338
44. Loo H, Dalery J, Macher JP. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders [in French]. Encephale 2002; 28 (4): 356-62
45. Kennedy SH, Rizvi S, Fulton K, et al. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008; 28: 329-33
46. Montejo AL, Prieto N, Terleira A, et al. Better sexual acceptability of agomelatine (25 and 50mg) compared with paroxetine (20 mg) in healthy male volunteers: an 8-week placebo-controlled study using the PRSEXDQ-SALSEX scale. J Psychopharmacol 2010; 24 (1): 111-20
47. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant agomelatine: randomized double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68: 1723-32 (Pubitemid 350247502)
48. Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized double-blind comparisonwith sertraline. J Clin Psychiatry 2010; 71 (2): 109-20
49. Montgomery SA, Kennedy SH, Burrows GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19 (5): 271-80 (Pubitemid 39141943)
50. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord 2007; 9 (6): 628-35 (Pubitemid 47365631)
51. Pjrek E, Winkler D, Konstantinidis A, et al. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology 2007; 190: 575-9 (Pubitemid 46204474)
52. Williams JBW, Link MJ, Rosenthal NE, et al. Structured interview guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder. 2002 rev. New York (NY): New York State Psychiatric Institute, 2002
53. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized doubleblind placebo-controlled study. J Clin Psychopharmacol 2008; 28: 561-6
54. Hamilton M. A rating scale for anxiety. J Neurol Neurosurg Psychiatr 1959; 23: 56-62
55. Fabiano A, de Leersnyder H. Agomelatine efficacy on major sleep disturbances in Smith-Magenis syndrome: an exploratory open study in children [abstract]. Eur Neuropsychopharmacol 2007; 17 Suppl. 4: S567
56. Kozian R, Syrbe G. QTc-Zeit-Verlangerung unter Therapie mit Agomelatin. Psychiat Prax 2010; 37: 405-7
57. National Taiwan University Hospital. The effect of agomelatine or fluoxentine on heart rate variability in patients with major depressive disorder [ClinicalTrials.gov identifier NCT00451490]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jul 13]
58. Dolder CR, NelsonM, SniderM. Agomelatine treatment of major depressive disorder. Ann Pharmacother 2008; 42: 1822-31
59. Harmer CJ, de Bodinat C, Dawson GR, et al. Agomelatine facilitates positive versus negative affective processing in healthy volunteer models. J Psychopharmacol. Epub 2010 Jul 21
60. Wisniewski SR, Rush AJ, Nierenberg AA, et al. Can phase III trial results of antidepressant medications be generalized to clinical practicé A STAR*D report. Am J Psychiatry 2009; 166: 599-607
61. Howland RH. Evaluating the safety of medications during pregnancy and lactation. J Psychosoc Nurs Ment Health Serv 2009; 47 (3): 19-22
62. Howland RH. Prescribing psychotropic medications during pregnancy and lactation: principles and guidelines. J Psychosoc Nurs Ment Health Serv 2009; 47 (5): 19-23
63. Trivedi MH, Rush AJ, Gaynes BN, et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care. Neuropsychopharmacology 2007; 32: 2479-89 (Pubitemid 350126843)
64. Servier. Efficacy of agomelatine in patients with obsessivecompulsive disorder [ClinicalTrials.gov identifier NCT01108393]. US National Institutes of Health, ClinicalTrials. gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2011 Jul 13]
65. Marqués Cabezas P, Cabus Piñ ol G, Coullaut-Valera García J, et al. Agomelatine in the treatment of obsessivecompulsive- disorder: potential for clinical effectiveness. A 4-week multicenter randomized placebo-controlled trial [abstract]. Eur Psychiatry 2011; 26 Suppl. 1: 974
66. Howland RH. Medication adherence. Psychiatr Ann 2008; 38 (5): 323-6
67. Howland RH. Limitations of evidence in the practice of evidence-based medicine. Psychiatr Ann 2008; 38 (5): 334-6
68. Wisniewski SR, Fava M, TrivediMH, et al. Acceptability of second-step treatments to depressed outpatients: a STAR*D report. Am J Psychiatry 2007; 164: 753-60 (Pubitemid 46808530)